Alide-P is commonly used to help with symptomatic relief by addressing symptom clusters that create noticeable physiological strain, and may contribute to supporting improved comfort and functional well-being during acute or episodic phases. One of its key components may be applied in addressing pain, including menstrual pain, which is an example of a condition involving inflammatory and recurrent symptomatic manifestations.

The combination is generally applied across therapeutic domains involving mild to moderate somatic pain, encompassing symptoms like headaches, general body aches, and discomfort related to minor injuries or illnesses. It is also considered relevant in conditions characterized by elevated body temperature (fever) and localized inflammatory or irritative states. Clinically, it is used for easing discomfort associated with primary dysmenorrhea and for managing pain and soreness following post-immunization care.

Quick Fact: Symptomatic Support for Pain, Fever, and Inflammation

The overall intent of use may be considered to offer short-term symptomatic assistance. The goal of symptomatic management is to support a patient's comfort during temporary periods of illness. This targeted application can offer support, which may help patients cope more steadily with difficult, acute, or cyclical episodes.

Regulatory References

1. NIH MedlinePlus overview

Alide-P is a medication for which specific regulatory guidelines strictly define eligible and non-eligible populations, primarily due to risks associated with its components.

Contraindications (Must Not Use)

Use of Alide-P is prohibited or contraindicated for:

• Individuals with a known hypersensitivity or allergy to Alide-P or any of its active components.
• Patients with severe heart failure.
• Individuals with a history of active or recurrent gastrointestinal bleeding, perforation, or peptic ulcers.
• Patients with severe kidney impairment or severe liver impairment.
• Children under 12 years of age (use is prohibited as per health guidelines).
• Women who are in the last trimester of pregnancy.

Restrictions and Special Consideration

The following groups should use the medicine with caution or are not recommended to take it:

• Older Adults (Elderly): Use requires caution due to an increased risk of severe adverse effects, particularly involving the kidney and stomach.
• Pregnancy and Lactation: Use is generally not recommended while breastfeeding or for women who are actively planning to conceive.
• Existing Conditions: Patients with pre-existing, non-severe kidney or liver problems should be closely monitored, and dosage adjustment may be necessary.

Consultation with a healthcare professional is mandatory to determine individual eligibility based on these official restrictions.

Interactions with other medicines and products

The interaction profile for Alide-P, a combination of Mefenamic Acid and Acetaminophen, is defined by constraints on co-administration and documented pharmacological effects on other medicines, as described in regulatory labels.

Contraindicated and High-Risk Combinations

Category	Official Interaction Statement
Other Acetaminophen Products	Co-administration is prohibited due to the risk of acute liver failure from exceeding the maximum recommended daily dose.
Other NSAIDs / Salicylates	Concurrent use is associated with a significantly increased risk of serious gastrointestinal events (e.g., bleeding, ulceration).

Pharmacological Effect and Substance Interactions

Co-administration with Antacids containing Magnesium Hydroxide is documented to significantly increase the rate and extent of Mefenamic Acid absorption. The NSAID component may cause increased plasma concentrations of Digoxin and Lithium.

Pharmacodynamic interactions include a reduction of the antihypertensive effect when combined with ACE Inhibitors, ARBs, or Beta-Blockers, and a reduction in diuretic efficacy with medicines like Furosemide or Thiazides. The combination with Warfarin or agents that interfere with hemostasis increases the risk of bleeding.

A specific substance constraint is documented for Alcohol (Ethanol): chronic consumption of three or more alcoholic drinks per day is associated with an increased risk of hepatotoxicity. Furthermore, co-administration with Cyclosporine may increase the risk of nephrotoxicity, particularly in patients with impaired renal function.

Molecular Blockade of Peripheral Signaling

This domain, driven by Mefenamic Acid, involves the inhibition of Cyclooxygenase (COX) enzymes at the site of physiological stress. This action restricts the enzymatic process that synthesizes local prostaglandins, which are key messengers that sensitize peripheral nerve endings, thereby resulting in reduced localized tissue signaling.

---

Central Modulation of Nociception and Temperature

The mechanism for this domain, primarily executed by Paracetamol, is centralized within the nervous system. It involves the inhibition of prostaglandin synthesis in the brain, particularly in the hypothalamus, alongside the modulation of central signaling pathways that process nociception. This dual effect supports the resetting of an elevated body temperature set point and contributes to the modulation of central nociceptive signal processing.

---

Mechanistic Cooperation across Systems

The drug's mechanism involves mechanistic cooperation (synergy) between its components, achieving a combined influence on nociceptive and thermoregulatory systems. By addressing the peripheral source of mediators while simultaneously modulating the central processing of the resulting signals, this mechanism influences multiple layers of physiological response, modifying peripheral signaling and central processing.

Alide-P, a combination product, is exclusively intended for oral administration, consistent with its common preparation as a liquid suspension for pediatric use. The usage protocol is defined by specific dose, frequency, and duration limits that restrict the medication to short-term use.

For adults and adolescents generally 14 years, the administration pattern involves an initial 500 mg dose followed by a 250 mg maintenance dose. This regimen is typically scheduled to be taken every six hours (q6hr) as needed (PRN). The total duration of use for this component, for general acute pain, must not exceed seven consecutive days. Treatment for cyclical pain, such as primary dysmenorrhea, is often restricted to the symptomatic period, generally two to three days.

Administration contextually allows for the medicine to be taken with food, milk, or a full glass of water to support gastrointestinal tolerability. For pediatric patients 6 months, the liquid suspension is used, and the dosage is determined on a weight-based calculation, with administration generally occurring three times daily (TID). Official guidance also provides the procedural rule that if a dose is missed, it should be skipped if the next scheduled dose is imminent, reinforcing that a double dose should not be taken.

Research Evidence / Overview of Studies for Alide-P

Research exploring the clinical profile of Alide-P, a combination medicine, focuses primarily on short-term Randomized Controlled Trials (RCTs) and systematic reviews for its individual components (Acetaminophen and Mefenamic Acid). These studies were conducted to examine outcomes related to managing episodic symptoms where physical discomfort is present, such as fever and mild to moderate acute pain.

Study Design and Measured Outcomes

For fever management (antipyresis), research examined the potential for a change in elevated body temperature, monitoring the time taken for an observable temperature change in pediatric populations. For acute pain, trials tracked patient-reported outcomes describing perceived discomfort, including pain intensity scores and the patient's ability to perform daily activities.

Evidence was also gathered for Primary Dysmenorrhea (menstrual pain), where studies focused on the Mefenamic Acid component and tracked changes in pain intensity over the acute episode (typically 1–5 days per cycle). Findings describe patterns observed in the studies related to short-term changes in these symptoms.

Research Gaps and Limitations

A key limitation in the evidence base is the lack of high-quality comparative trials that directly evaluate the specific, fixed-dose Acetaminophen/Mefenamic Acid combination product against its single components for all studied indications.

Furthermore, follow-up durations were consistently limited, restricting the available evidence to acute, short-term treatment courses. Consequently, long-term effects and extended-duration outcomes are not fully established. Data for certain special groups, such as older adults or those with pre-existing conditions, remain insufficient. The results apply only to the populations and short durations studied.

Key Studies & References The Antipyretic Effect of High-Dose Paracetamol Versus Mefenamic Acid in the Treatment of Febrile Children: A Randomized Control Trial

Common questions about Alide-P (FAQ)

---

Q: Why is the maximum duration only 7 days for adults?

Official prescribing information states that the use of this medicine for general acute pain relief must not exceed seven consecutive days. This time limit is based on regulatory guidance for the use of its Non-Steroidal Anti-Inflammatory Drug (NSAID) component, which is typically restricted to short courses for acute pain.

---

Q: What are the key differences between Alide-P and its components (Mefenamic Acid, Paracetamol)?

The fundamental difference is that the combination product provides a dual mechanism of action: one component manages pain and fever centrally, while the other addresses inflammation peripherally. While the combination offers this benefit, official regulatory sources note that comprehensive comparative trials directly evaluating the fixed-dose combination product against its individual components are limited.

---

Q: When should I take this medicine, before or after a meal?

Regulatory documents indicate that the medicine can be taken with food, milk, or a full glass of water. Taking the medicine this way is noted in the prescribing information as a way to potentially support gastrointestinal tolerability and reduce the chance of an upset stomach.

---

Q: How does this medication help with fever?

The Paracetamol component works within the central nervous system, specifically in the area of the brain called the hypothalamus. This action helps to reset the body's elevated temperature set point, which is the physiological process that lowers a fever.

---

Q: Can a 10-year-old child use this suspension?

Official health guidelines state that use of this medicine in the pediatric population under 12 years of age is generally restricted or prohibited. A healthcare professional should be consulted to determine individual eligibility, as use in this age group falls under specific regulatory restrictions.

---

Q: What is the specific maximum daily dose for Alide-P?

Because this medicine contains Acetaminophen, official information highlights the importance of carefully monitoring the total daily intake from all sources. There are strict limits defined by regulatory authorities to minimize the risk of serious side effects, such as acute liver failure. This is why it is essential not to exceed the dosage prescribed by a healthcare professional.

---

Q: How long does Alide-P take to start working?

According to the drug's pharmacokinetic data, the components are absorbed relatively quickly. The Paracetamol component can reach peak concentrations in the blood within 10 to 60 minutes, while the Mefenamic Acid component typically reaches its peak concentration within 2 to 4 hours after administration.

---

Q: How long after I stop taking Alide-P will it be completely out of my system?

The elimination of the medicine is related to the half-lives of its components. The elimination half-lives—the time it takes for half of the substance to be removed—are approximately two hours for Mefenamic Acid and one to three hours for Paracetamol, which serve as an indicator for the body's elimination rate.

How to Store and Dispose of Alide-P

Alide-P (Mefenamic Acid and Paracetamol Suspension) must be stored under specific environmental constraints to maintain its stability.

Storage Requirements

Requirement	Condition
Temperature	Store at room temperature, not exceeding 30 C.
Protection	Keep away from excess heat, moisture, and light.
Container	Keep the medicine in its original container with the cap tightly closed.
Safety	Store the product in a safe location out of the sight and reach of children and pets.

Disposal Instructions

Do not flush this medicine down the toilet or pour it down a drain. The official method for discarding unused or expired Alide-P is to use a drug take-back program. If one is unavailable, dispose of the medicine in the household trash by mixing it with an undesirable substance, such as dirt or used coffee grounds, and placing the mixture in a sealed plastic bag.